Skip to main content
    C

    CERo Therapeutics Holdings, Inc. Common Stock (CERO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • PINK

    $0.00
    +0.00 (+17.07%)

    Market Cap: $358,150

    Last updated: Nov 13, 2026 at 4:00 PM ET

    CERo Therapeutics Holdings, Inc. Common Stock (CERO) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    CERo Therapeutics Holdings, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$19.92M and operating cash flow was -$16.10M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of $4.02M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $18.46M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024N/AN/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Cost of revenue$0$1.16M$0$0N/A
    Gross profit$0-$1.16M$0$0N/A
    Research and development$10.38M$6.32M$5.29M$64.05K$9.14M
    Operating income-$18.46M-$15.30M-$7.68M-$2.91M-$332.03K
    Net income-$19.92M-$7.73M-$7.29M-$667.74K-$315.55K
    EBITDA-$18.24M-$6.57M-$6.25M-$2.91M-$332.03K
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Gross profit$0$0$0N/A$0$0$0$0$0-$288.16K-$284.75K$0
    Operating income-$3.19M-$3.85M-$4.85M-$4.43M-$4.36M-$4.72M-$4.95M-$4.40M-$5.15M-$4.55M-$1.29M-$1.54M
    Net income$4.02M-$1.03M-$5.89M-$4.54M-$4.86M-$5.42M-$5.11M-$4.23M-$2.45M-$2.30M-$1.41M-$1.35M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, the balance sheet showed $1.66M in cash and equivalents and no debt. Shareholder equity was negative, at -$5.45M, as total liabilities of $9.09M exceeded total assets of $3.64M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Total assets$3.64M$6.21M$5.13M$42.37M$180.08M
    Current assets$2.73M$3.71M$1.97M$42.37M$1.36M
    Cash and equivalents$1.66M$3.33M$1.60M$475.87K$1.10M
    Total liabilities$9.09M$8.10M$5.08M$39.90M$9.25M
    Short-term debt$0N/A$599.69K$650.00KN/A
    Shareholder equity-$5.45M-$1.89M-$42.06M-$11.00M-$7.67M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.83M$1.90M$2.21M$3.64M$3.91M$6.20M$7.99M$6.21M$6.49M$7.37M$9.05M$8.56M
    Total liabilities$20.67M$32.41M$11.46M$9.09M$8.45M$7.84M$8.32M$8.10M$10.19M$9.85M$13.03M$14.32M
    Cash and equivalents$530.68K$937.51K$857.49K$1.66M$2.02M$3.30M$5.20M$3.33M$3.38M$3.65M$4.59M$96.87K
    Shareholder equity-$18.84M-$30.51M-$9.26M-$5.45M-$4.54M-$1.63M-$329.39K-$1.89M-$3.70M-$2.48M-$3.98M-$5.76M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$16.10M-$5.79M-$5.79M-$1.09M-$697.11K
    Capital expendituresN/A$1$3$694.23K$612.57K
    Free cash flowN/A-$5.79M-$5.79M-$1.79M-$1.31M
    Share repurchases$500.42KN/AN/A$139.35MN/A
    Investing cash flow$500.00KN/A$0$180.84M-$178.50M
    Financing cash flow$13.92M$571.68K$571.68K-$138.70M$180.30M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$3.03M-$7.89M$2.80M-$3.83M-$3.21M-$4.62M-$4.45M-$2.76M-$3.54M-$5.08M-$960.77K-$1.32M
    Capital expendituresN/AN/AN/AN/A$0$0$4$0$4$2$0$0
    Free cash flowN/AN/AN/AN/A-$3.21M-$4.62M-$4.45M-$2.76M-$3.54M-$5.08M-$960.77K-$1.32M
    Last 12 quarters

    Frequently Asked Questions About CERO

    What is CERo Therapeutics Holdings, Inc. Common Stock's annual revenue?

    CERo Therapeutics Holdings, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is CERo Therapeutics Holdings, Inc. Common Stock profitable?

    No. CERo Therapeutics Holdings, Inc. Common Stock reported net income of -$19.92M for the fiscal year ended Dec 31, 2025.

    How much debt does CERo Therapeutics Holdings, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $1.66M.